Treatment of recalcitrant vulvovaginal gingival syndrome with adalimumab

Ho, Joyce K; Hantash, Basil M.

doi:10.1016/j.jaad.2010.10.034

Cited by 7 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An improvement of erosive OLP was reported in a patient treated with etanercept ( 28 ). Furthermore, a patient with a severe orogenital LP was successfully treated with infliximab ( 27 ) and two other patients with a severe orogenital involvement were treated with adalimumab ( 29 , 30 ). However, emerging data suggest that TNF-alpha inhibitors may trigger OLP ( 31 , 32 ).…”

Section: Biologicsmentioning

confidence: 99%

Therapeutic strategies for oral lichen planus: State of the art and new insights

et al. 2022

View full text Add to dashboard Cite

Oral lichen planus (OLP) is a chronic inflammatory disease of the oral mucosa. Several clinical subtypes of OLP have been reported, including the reticular and erosive one. On the one hand, reticular OLP is usually asymptomatic and is characterized by white streaks surrounded by well-defined erythematous borders. On the other hand, erosive OLP shows ulcerations and erosions surrounded by erythematous mucosa. While reticular OLP is relatively easy to control, erosive OLP is extremely painful and refractory to therapies, limiting the quality of life of the patients. In addition, treating erosive OLP is extremely tricky, and a gold standard treatment has not yet been established. However, several therapeutic approaches have been reported as effective, including systemic corticosteroids, systemic retinoids, and anti-interleukin (IL)-17/anti-IL-23 drugs. Indeed, our group and other several authors reported the effectiveness of anti-IL17, anti-IL12/23, and anti-IL23 agents in refractory OLP, highlighting the urgency of clinical studies on the use of anti-IL agents in OLP patients. In this paper, we reviewed the English- and German-language literature about therapeutic strategies for treating OLP, focusing on new systemic therapies for erosive OLP.

show abstract

Section: Biologicsmentioning

confidence: 99%

Therapeutic strategies for oral lichen planus: State of the art and new insights

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Response to TNF‐α blockade in patients with LP requiring but refractory to or intolerant of systemic immunosuppressants has also been reported. These include one patient with severe erosive oral LP responding to etanercept (Yarom, 2007) and two with mucocutaneous LP with severe orogenital involvement responding to adalimumab (Chao, 2009; Ho and Hantash, 2011). An additional case of severe orogenital LP responding to infliximab has also been presented (Muller et al , 2008).…”

Section: Lichen Planusmentioning

confidence: 99%

“…Subsequently reported, as part of a small case series of (predominantly genital) mucosal erosive LP, were two patients with concomitant oral disease, each of which responded to treatment with alefacept, as measured by improved disease and mucosal pain scores for both disease sites (Chang et al, 2008). However, no follow-up data were provided, and additional patients who received a placebo treatment also (Yarom, 2007) and two with mucocutaneous LP with severe orogenital involvement responding to adalimumab (Chao, 2009;Ho and Hantash, 2011). An additional case of severe orogenital LP responding to infliximab has also been presented (Muller et al, 2008).…”

Section: Lichen Planusmentioning

confidence: 99%

Biologics in oral medicine: ulcerative disorders

O’Neill¹,

Scully²

2012

Oral Diseases

View full text Add to dashboard Cite

Inflammatory ulcerative diseases of the oral mucosa are wide ranging but include especially aphthous and aphthous-like ulceration, vesiculobullous disorders and erosive lichen planus (LP). While most patients with these conditions respond to conventional topical and/or systemic immunosuppressive agents, treatment-resistant cases remain challenging. In these, the use of biologics such as tumour necrosis factor alpha (TNF-α) inhibitors or rituximab may be of benefit. This article reviews the use of biologics in ulcerative oral conditions, highlighting potential benefits, adverse effects and principles of use and future developments. TNF-α inhibitors such as infliximab can be effective in inducing resolution in oral aphthous and aphthous-like ulcers and may be an appropriate therapy in those patients in which disease is severe and refractory to, or patients are intolerant of, traditional immunomodulatory regimens. There would also seem support and rationale for use of biologics (mainly rituximab) in pemphigus but not in oral LP or other oral ulcerative conditions.

show abstract

“…), ретиноидами [14] или ингибиторами кальциневрина (мазь такролимус) [10]. При резистентности к лечению и распространенных процессах проводят системную терапию преднизолоном, азатиоприном, циклоспорином, гризеофульвином, ацитретином, синтетическими антималярийными препаратами, метронидазолом [8,15], а также биологическими препаратами, в частности адалимумабом [16].…”

unclassified

A novel approach to the treatment of vulvovaginal gingival syndrome

Molochkova¹,

Молочков²,

Amkhadova³

2018

Klin. dermatol. venerol.

View full text Add to dashboard Cite

Красный плоский лишай (КПЛ)-воспалительное заболевание кожи, слизистых оболочек, волос и ногтей с подострым или хроническим течением, имеющее характерные клинические и гистологические особенности [1]. Наиболее частым проявлением КПЛ является поражение слизистых оболочек (популяционная частота 1-2%), около 25% больных КПЛ женщин имеют вульвовагинальные пора жения [2, 3]. Выделяют также вульвовагинально-гингивальные и вульвавагинально-гингивально-аналь

show abstract

Treatment of recalcitrant vulvovaginal gingival syndrome with adalimumab

Cited by 7 publications

References 2 publications

Therapeutic strategies for oral lichen planus: State of the art and new insights

Therapeutic strategies for oral lichen planus: State of the art and new insights

Biologics in oral medicine: ulcerative disorders

A novel approach to the treatment of vulvovaginal gingival syndrome

Contact Info

Product

Resources

About